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Summary 
FK-506 inhibits Ca2+-dependent transcription of lymphokine genes in T cells, and thereby acts 
as a powerful immunosuppressant. However, its potential therapeutic applications may be seriously 
limited by several side effects, including nephrotoxicity and neurotoxicity. At present, it is unclear 
whether these immunosuppressive  and toxic effects result from interference with rehted biochemical 
processes. FK-506 is known to interact with FK-binding protein-12 (FKBP-12), an abundant 
cytosolic protein with cis.trans peptidyl-prolyl isomerase activity (PPlase) activity. Because rapamycin 
(RAP) similarly binds to FKBP-12, although it acts in a manner different from FK-506, by inhibiting 
T cell responses to lymphokines, such an interaction with FKBP-12 is not suf~cient to mediate 
immunosuppression. Recently, it was found that the complex of FKBP-12 with FK-506,  but 
not with RAP, inhibits the phosphatase activity of calcineurin. Here, we used b685,818, the 
C18-hydroxy,  C21-ethyl derivative  of FK-506,  to explore further the role of FKBP-12 in the 
immunosuppressive and toxic actions of FK-506. Although b685,818 bound with high af~nity 
to FKBP-12 and inhibited its PPlase activity,  it did not suppress T  cell activation, and, when 
complexed with FKBP-12, did not affect calcineurin phosphatase activity.  However,  b685,818 
was a potent antagonist of the immunosuppressive activity of both FK-506 and RAP. Moreover, 
L-685,818 did not induce any toxicity in dogs and rats or in a mouse model of acute FK-506 
nephrotoxicity, but it blocked the effect of FK-506 in this model. Therefore, FK-506  toxicity 
involves the disruption of biochemical mechanisms related to those implicated in T cell activation. 
Like immunosuppression,  this toxicity is not due to the inhibition of the PPlase activity of FKBP-12, 
but may be linked to the inhibition of the phosphatase activity of calcineurin by the drug FKBP-12 
complex. 
F 
K-506,  rapamycin (RAP) 1,  and cyclosporin A  (CsA), 
define a class of immunosuppressive  natural products that 
have in common the ability to inhibit T lymphocyte activa- 
tion by interfering with intraceUular signaling mechanisms 
(1,  2).  However, these agents affect different biochemical 
pathways within the cascade of events that culminate in the 
expression ofT cell effector functions. Both FK-506 and CsA 
disrupt T  cell signaling pathways  associated with a rise in 
the  concentration  of intracellular  Ca  2+  (3,  4),  and  this 
results in the inhibition of the transcription of a family of 
early activation genes, including IL-2 and IL-4 (5-7). In con- 
1 Abbreviations used in  this paper: BUN,  blood  urea nitrogen;  CsA, 
cyclosporin  A; Cyp, cyclophilin;  FKBP-12, FK-binding  protein-12; PPIase, 
peptidyl-prolyl isomerase activity; and RAP, rapamycin. 
trast,  RAP does not inhibit Ca2+-dependent lymphokine 
gene expression  (5, 3), but impairs the response of T  cells 
to growth-promoting lymphokines (3). Furthermore, FK- 
506 and RAP potentiate the immunosuppression  induced by 
CsA (8, 9), whereas, under certain conditions, they antagonize 
each other's immunosuppressive action (9). 
Despite thdr exquisite specificity for certain steps in T signal 
transduction, these immunosuppressants have significant in 
vivo toxicity. The adverse effects of FK-506 and CsA are very 
similar an include neurotoxicity and nephrotoxicity (10, 11), 
whereas RAP exerts little nephrotoxicity, but induces vascu- 
litis (12) and myocardial necrosis (13). These toxic manifesta- 
tions are of particular concern as they impose severe limita- 
tions  in  the  potential  therapeutic  application  of  these 
immunosuppressants. At present, it is unclear whether ira- 
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teration  by the  drugs  of similar  biochemical  processes  in 
different cell types. 
At the biochemical level,  FK-506 and CsA interact with 
two distinct  families of intraceUular  proteins,  termed  FK- 
binding proteins (FKBPs) (14) and cyclophilins (Cyps) (15), 
respectively. Despite its contrasting biological activity profile, 
RAP binds to the same FKBP protein family as FK-506 (16, 
17). The two major forms of each of these receptor types, 
FKBP-12 and Cyp A, are peptidyl-prolyl cis-trans isomerases 
(PPlases), and catalyze the interconversion of the c/s and trans 
rotamers of the peptidyl-prolyl amide bonds of peptide and 
protein substrates (16,  18,  19). FK-506, RAP, and CsA in- 
hibit the PPIase activity of their respective binding proteins 
(16,  18-20). However, inhibition of this enzymatic activity 
is not sufficient to explain the biological activities of these 
immunosuppressants.  We demonstrated that  a CsA analog 
that inhibited Cyp A PPlase activity was neither immunosup- 
pressive nor nephrotoxic, whereas another analog, which had 
little or no activity as a PPlase inhibitor,  exhibited immunosup- 
pressive activity (21).  The similar potencies of FK-506 and 
RAP in inhibiting the PPlase activity of FKBP-12 also sug- 
gested a dissociation between this inhibition  and the mode 
ofimmunosuppressive action of the macrolides (22). Moreover, 
a synthetic compound (506BD), corresponding to the por- 
tion of the FK-506 molecule that  binds  to FKBP-12 (23), 
was found to block the PPIase activity of this protein without 
exerting  significant  immunosuppression  (22). 
The discovery that  the molecular complexes formed be- 
tween FK-506 and FKBP-12 or between CsA and Cyp A bind 
to  the  Ca  2+-  and  calmodulin-dependent  serine/threonine 
phosphatase, calcineurin (24, 25), and inhibit its enzymatic 
activity (26), may explain how these compounds exert their 
immunosuppressive effects.  Since a RAP:FKBP-12 complex 
does not inhibit calcineurin phosphatase activity, the obser- 
vations  also  provide  an  explanation  for  the  mechanistic 
similarity between FK-506 and CsA. However, because the 
nonimmunosuppressive compound 506BD was found capable 
of inhibiting calcineurin phosphatase activity by up to 40% 
(26), additional studies with other macrolide analogs appear 
necessary to establish the relevance  of these in vitro effects 
to immunosuppression. 
In the present work, we describe b685,818, a novel nonim- 
munosuppressive FK-506 relative,  and use this molecule as 
a probe to further explore the mechanisms of action of FK- 
506 and RAP.  b685,818 is the C18-hydroxyl derivative of 
L-683,590, which differs from FK-506 by a single allyl to ethyl 
substitution at the C21 position of the macrolide ring (27). 
We found that b685,818 binds to FKBP-12 and inhibits its 
PPlase activity. However, the FKBP-12:b685,818 complex 
was unable to inhibit calcineurin  phosphatase activity, in con- 
trast to the FKBP-12:b683,590 complex which was half as 
active as the FKBP-12:FK-506 complex in this assay. Moreover, 
L-685,818 behaved as a potent competitive antagonist of the 
inhibitory effects of both FK-506 and RAP, but not of CsA, 
in models of T  cell activation in vitro. Although L-685,818 
had no detectable toxicity in vivo, it proved to be an effective 
antagonist  of FK-506, but not of CsA, in a murine model 
of drug-induced nephrotoxidty. Altogether, these studies with 
L-685,818, clearly show that the inhibition of FKBP-12 PPIase 
activity is not involved in either the immunosuppressive or 
toxic effects of FK-506. Moreover, there exists a mechanistic 
relationship between these two types of biological effects of 
the drug, that may be linked to the inhibition of calcineurin 
phosphatase  activity. 
Materials and Methods 
Mice.  Female  C57B1/6 and BALB/c mice (6-12-wk-old) were 
obtained from the Jackson Laboratory (Bar Harbor, ME) or from 
Taconic Farms (Germantown,  NY), and maintained under specific 
pathogen-free  conditions  until use. 
Reagents.  FK-506  and RAP were isolated by Dr. Robert Borris, 
at Merck Research Laboratories (MR.L, Rahway, NJ) from Strep- 
torayces  tsukubaensis  and  Streptomyces  hygroscopicus,  respectively. 
b683,590 (FK-520) was isolated from S. hygroscopicus vat. ascomycetus 
by Drs. Kevin Byrne and Gino Salituro (MRL). b685,818 was syn- 
thesized by chemical modification of 1,683,590 as described else- 
where (Beattie, T., B. Arrison,  and M.  Wyvratt, manuscript  in 
preparation). Tritiated dihydro-FK-506 was provided by Dr. Allen 
Jones (MRL). CsA was provided by Dr. Philippe Durette (MILL). 
PMA and ionomycin were from Sigma Chemical Co. (St. Louis, 
MO) and Calbiochem Corp. (La JoUa, CA), respectively.  SKF-525A 
was obtained  from  Research Biochemicals Inc. (Natick,  MA). 
Recombinant  human  IL-lc~ was provided by Dr. Jack  Schmidt 
(Merck Sharp & Dohme Research Laboratories).  Recombinant 
human  Ib2 was purchased from Amgen Biologicals (Thousand 
Oaks, CA). Inhibitor I peptide (28) was obtained from Dr. Philip 
Cohen (University of Dundee, UK). The routine Ib2 and IFN-3, 
cDNA probes were obtained from Dr. Bill Gauss (National  Ins- 
titutes  of Health,  Bethesda,  MD) and from  Dr.  Gordon Free- 
man (Dana-Farber Cancer Institute,  Boston,  MA),  respectively. 
The ~8-actin cDNA probe was obtained from Oncor Inc. (Gaithers- 
burg,  MD). 
Cell Cultures.  Splenic  T cells from C57B1/6 mice were isolated 
by nylon wool separation as previously described (3). The DO- 
11.10 T cell hybridoma (29) was provided by Dr. Philippa Marrack 
(National Jewish Center for Immunology and Respiratory Medi- 
cine, Denver, CO).  The YAC-1 T cell lymphoma  was obtained 
from the American Type Culture Collection (Rockville, MD). Cells 
were grown in culture medium made up of RPMI 1640 medium 
(Gibco, Grand Island, NY) supplemented with 10% heat-inactivated 
FCS, 2 mM glutamine,  1 mM sodium pyruvate, 2  ￿  10-5 M 2- 
ME, and 50 #g/ml gentamycin. Microcultures of splenic T cells 
were set up in flat bottomed 96-well plates (Costar Corp.,  Cam- 
bridge, MA). Each well received 200 gl of cell suspension at 106 
cells/ml. The T cell activators and various combinations  of com- 
pounds were set up in triplicate wells. The plates were incubated 
at 37~  in a humidified atmosphere of 5% CO2-95%  air. Cul- 
tures were pulsed with [3H]TdR (2 #Ci/well) for the last 4-5 h 
of a 48-h incubation period and harvested on glass fiber filters. In- 
corporated radioactivity was measured by using a Betaplate liquid 
scintillation spectrometer (Pharmacia-LKB, Piscataway, NJ). Cell 
cultures for analysis of mKNA expression were set up in 25-cm  z 
tissue culture flasks (Coming Glass Works, Coming, NY) main- 
tained in an upright position.  DO-11.10 cells (2  x  10  s cells/ml) 
were stimulated with ionomycin plus PMA in the presence or ab- 
sence of drugs, and harvested for RNA extraction after 3 h of cul- 
ture.  YAC-1 cells (10  s cells/ml)  were  incubated  with  Ibl  plus 
PMA in the presence or absence of drugs, and RNA was extracted 
after 20 h of culture. 
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isolated using RNAzol (Cinna/BioTeck, Friendswood, TX). RNA 
samples were blotted onto nitroceUulose filters using a slot-blot 
Minifold II apparatus (Bio-Rad Laboratories, Richmond, CA). The 
cDNA probes were labeled with [32p]dCTP to high specific ac- 
tivity using a random primed DNA labeling kit (Boehringer Mann- 
helm,  Indianapolis,  IN).  R.NA blots  were  prehybridized  and 
hybridized with the probes and autoradiographed using Hyperfilm- 
ECL (Amersham Corp.,  Arlington Heights,  IL). 
FKBP Binding Assay.  Human FKBP-12 was purified as previ- 
ously described (19). An LH-20 column binding assay (15) was used 
for competitive binding studies. Compounds were dissolved in eth- 
anol and diluted in 20 mM sodium phosphate containing 0.5% 
BSA (binding buffer). The reaction was set up in siliconized  round- 
bottomed 96-well plates. To 175 #1 of binding buffer, 25 #1 of the 
competitor compound solution, 25/~1 of FKBP-12 at 250 ng/ml, 
and 25/~1 of [3H]dihydro-FK-506 at 10 ng/ml, were added into 
each well. After mixing and 20 min incubation at 20~  the bound 
[3H]dihydro-FK-506  was separated from free ligand by passing over 
a 2-ml LH-20 micro-column (Pharmacia-LKB). The column was 
eluted with 500/~1 of 20 mM sodium phosphate, and the void 
volume counted for radioactivity. Determinations  were made in 
duplicate and the ICs0 calculated by linear regression on serial di- 
lutions  of competitor. 
FKBP-12 PPIase Assay.  The PPlase activity of FKBP-12 was 
assayed as previously described (20) by measuring the c/s to trans 
isomerization of the proline-phenyhhnine peptide bond in the pep- 
tide,  Suc-Ala-Leu-Pro-Phe-pNA. Under equilibrium  conditions, 
'-88% of the peptide is present as the trans form and is readily 
cleaved  by chymotrypsin. The remaining 12% of the peptide present 
in the c/s form is cleaved upon enzymatic conversion to the trans 
form. The size of conversion was monitored by the change in ab- 
sorbance at 390 nM because of the release ofp-nitroaniline.  The 
compounds were tested in 4-ml cuvettes containing  2.8 ml of a 
70 mM solution of the substrate in assay buffer (35 mM Hepes, 
pH 7.8, 3% DMSO) to which were added 30/~1 ofa 1.2-mM solu- 
tion of FKBP-12. Various dilutions of compound in 10/~1 ethanol 
were added, and the resulting solution was left to reach thermal 
equilibrium at 10~  for 10 rain. The reaction was initiated by ad- 
dition of 100 #1 of a 2.2-mM solution of chymotrypsin in 1 mM 
HCI, and absorbance was recorded. The first order portion of the 
resulting progress curve was fit to a simple first order rate equa- 
tion. The rate constants determined from the enzymatic isomerase 
activity was first corrected for the rate of nonenzymatic isomeriza- 
tion. This value, k~,~hb, divided by the rate constant for the reac- 
tion in the absence of inhibitor, k~  .....  l, was plotted as a function 
of inhibitor concentration.  The resulting plot was fit to a model 
for tight binding  inhibition  to obtain K1 and [Eo]. 
Phosphatase Assay of Cakineurin.  The assay was modified from 
the procedures described by Manalan and Klee (30) and Lin et al. 
(26). Inhibitor I peptide (28), which was phosphorylated with 321). 
labeled ATP (450 cpm/pmol) with the catalytic subunit of cAMP- 
dependent protein kinase, was used as a substrate. The assay buffer 
consisted of 40 mM Tris-HCl  (pH 7.5),  0.1  M  NaC1, 6 mM 
MgC12, 0.1 mM CaC12, 0.1 mg/rrd BSA, and 0.5 mM dithiothre- 
itol. The assay mixture (60/~1) contained 3 nM bovine brain cal- 
cineurin (Sigma), 190 nM calmodulin (Sigma), 420 nM recombinant 
human FKBP-12  and 7/~M ofphosphopeptide.  The drug solutions 
were prepared in DMSO at concentrations of DMSO <0.04% in 
the final assay mixture.  The incubation was carried out at 30~ 
for 10 min before the reaction was stopped and loaded onto 0.5-ml 
Dowex  AG  50W-X8 (200-800  mesh;  Bio-Rad  Laboratories) 
columns. The level of [32p] eluted from the columns was deter- 
mined by liquid scintillation radioactivity measurement. 
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Toxicological Evaluation ofL685,818 in Dogs and Rats.  Beagle 
dogs (two males and two females per group) or Sprague-Dawley 
rats (10 males and 10 females/group) were treated daily for 14 d 
with L-685,818 or the vehicle only. L685,818 was administered by 
oral gavage as a suspension in 0.5% methylcellulose, at a dose of 
25 mg/kg/d. The animals were observed daily for mortality and 
clinical signs of drug effect. Body weight and food consumption 
were also monitored. During the second  week of  treatment, hemato- 
logic and serum biochemical examinations and urinalysis were con- 
ducted. For the dog study, plasma drug level determinations were 
made on the first day of treatment and at study determination. 
At necropsy, gastrointestinal tract,  liver, kidneys, spleen, lymph 
nodes, and thymus were examined for any gross lesions. Specimen 
of these tissues were preserved in 10% neutral buffered formalin 
and examined microscopically  using paraffin-embedded and hema- 
toxylin/eosin-stained sections. 
Murine Acute Nephrotoxicity Assay.  Treatment with the cyto- 
chrome P450 inhibitor, SKF-525A (31), was used to enhance the 
toxicity of FK-506 in BALB/c mice (Koprak, S., and F. Dumont, 
manuscript in preparation). SKF-525A was dissolved in saline, and 
a dose of 75 mg/kg was injected intraperitoneally 2 h before intra- 
venous injection of 0.5 ml of the compound or vehicle control so- 
lutions. Stock solutions of compounds were made up in ethanol 
at  65  rag/m1,  further  diluted  in  ethanol,  and  mixed  with 
Cremophor  |  (BASF, Parsippany, NJ) followed by saline, to give 
final solutions containing 10% (wt/vol) Cremophor  |  and 6% eth- 
anol. The vehicle control solution was made up of saline with the 
same concentrations  of Cremophor  |  and ethanol.  The mice re- 
ceived these injections for 2 consecutive d and were killed the fol- 
lowing day for autopsy and collection of serum and tissue (kidney, 
liver) samples. Measurement of blood urea nitrogen (BUN) levels 
in the serum was done on an autoanalyzer (model 203; Gilford 
Instrument Laboratories, Inc., Oberlin,  OH). 
Results 
L.685,818 Binds to FKBP-12 and Inhibits its PPIase Activity 
but Does Not Inhibit T  Cell Activation.  As shown in Fig. 1, 
the chemical structure of b685,818 is closdy related to that 
of FK-506. L-685,818 was synthesized from I.-683,590, which 
differs from FK-506 by an ally1 to ethyl substitution at the 
C21 position (27). b685,818 also contains a hydroxyl group 
at the C18 position of the macrolide ring. Consistent with 
their  structural  similarity to FK-506, both L-685,818  and 
I--683,590 bind to FKBP-12 with a high af~nity (Fig. 2 a). 
Furthermore, L-685,818 is a potent inhibitor of the PPlase 
activity of this protein, comparable with FK-506 or RAP 
(Fig.  2  b). 
In  contrast  to  its  activity in  these biochemical  assays, 
1.-685,818 did not inhibit the proliferation of T cells activated 
by ionomycin plus PMA, even when tested at concentrations 
up to five orders of magnitude >FK-506 (Fig.  2 c). Under 
the same conditions, L-683,590  was only threefold less po- 
tent than FK-506, in agreement with earlier studies (27). 
I--685,818, at concentrations as high as 25/~M, also had little 
effect on IL-2 plus PMA-induced T cell proliferation, whereas, 
as previously reported (3), such a response was suppressed 
by subnanomolar concentrations of RAP  (Fig.  2 d). 
The Complex FKBP12:L685,818 Does Not Inhibit Cakineurin 
Phosphatase Activity.  It was reported recently that the mo- 
lecular complex formed between FKBP-12 and FK-506 is able 
to inhibit the Ca2+/calmodnlin-dependent phosphatase ac- (3H3  '":  OH  CH  3  '  !  OH  CH3  '  !  OH 
?  %  I"..,,/~  ?  %  V..,,/*  ?  %  ]-..,,,/* 
O~ 0  CH3~.  J  0/~  0  CH3~J  0'~  "0 ~  CH3~.  J 
(3H3~0~'~,~  (3H3,1L.  7  CH:3~O"~  (3HI.  7  (3H3EO'I~"JL. (3Hll.  7 
CHIO  OCH3  (3H30  OCH  3  CH30  OCH  3 
FK-506  L-683,590  L-685,818 
Figure  1.  Comparison of  the  chemical 
structures  of  I~-506,1,683,590 (FK-520), and 
1,685,818. Note the C21 ethyl  substitution  in 
I~683,590 (*) and the C18 hydr~yl substitu- 
tion in 1,685,818 (**). 
tivity of calcineurin in vitro (26). We wished to address the 
possibility that the lack of biological activity of L-685,818 
was due to its inability to inhibit calcineurin phosphatase in 
the presence  of FKBP-12. As shown in Fig. 3, when tested 
under experimental conditions where FK-506 and L-683,590 
could block caldneurin function with EDs0s of 57 and 108 
riM, respectively,  L-685,818 was totally inactive at concen- 
trations up to 2 #M. Consistent with the data of Liu et al. 
(26),  RAP also failed to suppress  the phosphatase activity 
of caldneurin, even at concentrations 40-fold higher than 
FK-506. 
L685,818 Antagonizes the Suppressive E.~ects of FK.506 and 
RAP on T Cell Proliferative  Responses.  These observations, 
together with our earlier finding of a mutual antagonism 
between FK-506 and RAP (9), prompted us to examine the 
possibility that I~685,818 might be a functional antagonist 
of these macrolides. We first tested whether b685,818 would 
block the inhibitory effect of  FK-506 in ionomycin  plus PMA- 
stimulated T cells. FK-506 was used at 1.2 nM, a concentra- 
tion that suppressed  the proliferation by 93-97%,  and vat- 
ious concentrations of L-685,818 were added simultaneously. 
As shown in Fig. 4 a, concentrations of L-685,818 >100 nM 
completely reversed the suppressive effect of FK-506. There- 
fore,  1,685,818  is a potent antagonist of FK-506 (EDs0  -- 
63.1  _+  7.2 ruM, mean  _+  SEM of 13 experiments). In con- 
trast, L-685,818 failed to reverse the inhibitory effect of CsA 
in T cell cultures similarly stimulated with ionomycin plus 
PMA (Table 1). 
The Schild analysis method is used to determine the affinity 
of a pharmacological antagonist in a biological system (32), 
and was employed here to further evaluate the antagonist ac- 
tivity of L-685,818. T cells stimulated with ionomycin plus 
PMA were cultured in the presence of vafious concentrations 
of FK-506 either alone or together with increasing concen- 
trations of L-685,818. Fig. 4 b demonstrates that addition of 
1,685,818 concentrations ranging from 19 nM to 2.5/~M pro- 
gressively shifted the dose-response inhibition curve of FK- 
506 to the fight, indicating a decreased sensitivity of the ceils 
to the immunosuppressant. Calculation of the EDs0s of the 
inhibitory effect of FK-506 in the absence or presence of vat- 
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Figure 2.  1,685,818  (A) binds to FKBP-12  (a) and inhibits 
its PHase activity  (b), but does not inhibit the proliferative 
responses of T ceils stimulated,  either with ionomycin  plus 
PMA (c), a mode of activation  sensitive  to FK-506 (O) and 
1,683,590 (A), or with I1,2 phs PMA (d), a mode  of activa- 
tion sensitive  to RAP (r-I). The binding  to FKBP-12  was de- 
termined in a competitive  assay  using [3H]dihydro-FK-506. 
The EDsos for each compound  are indicated on the figure. 
The inhibition  of  PPlase activity  of  FKBP-12  was very  similar 
for the three compounds  examined. The line corresponds to 
the best fit calculated  by a nonlinear  regression  analysis,  Mouse 
splenic T cells were cultured with ionomycin  (250 ng/ml) 
plus PMA (10 ng/ml) or with IL-2 (100 U/ml) plus PMA 
(10 ng/ml)  in the presence of  various concentrations  of  com- 
pounds, and the cell proliferation  was measured  by [3H]TdR. 
uptake after  2 d of  culture. The results  were expressed  as per- 
cent of the control [3H]TdR incorporation  in cultures that 
received the stimuli  only (ionomycin -  PMA -  467 x 103 
cpm, I1,2 + PMA  = 550  x  103 cpm). 
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Figure 3.  Effects of  various 
concentratiom of FK-506  (0), 
b683,590 (A),  b(,s5,818 (121) and 
RAP (A) on the phosphatase ac- 
tivity of bovine brain calcineurin 
(3  riM)  tested  towards  32p. 
inhibitor  I peptide (7/LM), in the 
presence  of bovine calmodulin 
(190 nM) and of recombinant 
human FKBP-12 (420  nM). The 
results were expressed as percent 
of the control phosphatase activity 
obtained in the absence of any 
compound. The lines correspond 
to the four-parameter  fits of in- 
dividual experimental points.  In 
this experiment,  FK-506 gave an 
ICs0  -  57  nM  and L-683,590 
gave an ICs0  =  108 nM. 
ious concentrations of L-685,818 allowed us to characterize 
the interaction of the two macrolides with their common 
receptor. The data plotted in Fig. 4 c indicate that L685,818 
competes with FK-506 for a single functional receptor in T 
cells (32). As calculated by this method, the Ka of the in- 
teraction of L-685,818 with this putative receptor is 8.7  + 
1.0 nM (mean  _+  SEM of four experiments). 
We next examined whether L-685,818 would reverse the 
immunosuppressive effect of RAP in T cells stimulated with 
ID2 plus PMA. Using RAP at a concentration of 1.1 nM, 
which inhibited the proliferative response by 70-75%,  the 
addition of 1.-685,818 resulted in a dose-dependent restora- 
tion of the proliferative response, with an EDs0 --  45.5  + 
6.0 nM (mean •  SEM of six experiments),  as shown in Fig. 
4 d.  Schild analysis (Fig. 4, e and J) further demonstrated 
that L-685,818 acts as a competitive antagonist of RAP at 
the level of a single functional site with a Ka of 4.4  •  0.5 
nM (mean •  SEM of  three experiments). This value is close, 
but not identical to the Ka determined for FK-506 compe- 
tition (Student's t test, p  =  0.03). 
1_,685,818 Reverses the Immunosuppressive  E~ects of FK-506 
or RAP Even When Added Late into the Cultures.  Experiments 
were then conducted to define the temporal site of this an- 
tagonistic effect of  L685,818. Fig. 5 a demonstrates that, when 
added as late as 6 h after FK-506 in T cell cultures activated 
with ionomycin plus PMA, b685,818  still fully restored the 
proliferative response measured at 48 h of culture. L-685,818 
also reversed the inhibition of PAP by more than 50% even 
when added up to 12 h after the latter to cuhures stimulated 
with Ib2 plus PMA (Fig. 5 b). Therefore, L-685,818 com- 
petes at the level of the functional receptors that mediate the 
pharmacologic action of the immunosuppressants, rather than 
at the level of a transport mechanism necessary for entry of 
the macrolides into the cell. 
1-,685,818 Antagonizes the Suppressive  Effects of FK-506 and 
RAP on Lymphokine mRNA  Induction.  To confirm that 
1-685,818 acted as an antagonist at the level of transcriptional 
regulation, we studied its effect on IL2 mKNA induction 
in DO-11.10 hybridoma T cells activated with ionomycin plus 
100, 
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Figure 4.  L-685,818  antagonizes the immunosuppressive effects of FK- 
506 (a-c) and RAP (d-J~ in activated T cells. (a) Mouse splenic T cells 
were activated with ionomycin plus PMA in presence of 1.2 nM FK-506, 
and various concentrations  of b685,818 were added at the initiation of 
the cultures. (b) Mouse splenic T cells were activated with ionomycin  plus 
PMA  in presence  of various  concentrations of FK-506  either  alone 
(O - - O) or with b685,818 at concentrations increasing in twofold incre- 
ments from 19 nM to 2.5/~M. (c) Schild analysis of the antagonism of 
FK-506 by b685,818 in the experiment depicted in (b). (d) Mouse splenic 
T cells were activated with IL-2 plus PMA in presence of 1.1 nM RAP, 
and various concentrations of b685,818 were added at the initiation of 
the cultures. (e) Mouse splenic T cells were activated with II=2 plus PMA 
in presence of various concentrations of RAP, either alone (O-O) or with 
L-685,818 at concentrations increasing in twofold increments from 19 nM 
to 2.5/~M. (f) Schild analysis of the antagonism of RAP by L-685,818 
in the experiment  depicted in (e). 
PMA. Fig. 6 a shows that Ib2 mRNA was detectable 3 h 
after activation  and was  inhibited by FK-506 in  a  dose- 
dependent manner. L685,818 had no effect on this induction 
of ID2 mRNA expression, but it blocked the inhibitory effect 
of FK-506. In a different modal of lymphokine gene regula- 
tion, the induction of IFN-'y mRNA by IL-1 plus PMA in 
the YAC-1 T  cell lymphoma (33), PAP was inhibitory at 
concentrations as low as 1 nM (Fig. 6 b). b685,818,  tested 
at 12/~M, did not inhibit IFN-3, mRNA expression and to- 
tally restored this expression in PAP-treated cultures. 
1..685,818 Is Not Toxic in Dogs andRats.  Based  on the afor~ 
mentioned data, b685,818  appeared as an excellent tool to 
address the question of the mechanistic relationship between 
F~-506 immunosuppression and toxicity. First, we investigated 
755  Dumont et al. Table  1.  L-685,818 Does Not Block the Suppressive Effect of CsA  in  T  Cells Stimulated with Ionomycin Plus PMA * 
T call proliferation ([3H]TdR uptake)t 
No L-685,818  + L-685,818 (25/~M) 
CsA concentration  cpm  x  10 -35  Percent control II  cpm  x  10 -3  Percent  control 
nM 
0  341.0  100.0  332.6  100.0 
6  355.8  104.3  395.3  118.9 
12  340.2  99.8  377.1  113.4 
25  355.6  104.3  268.8  80.8 
50  161.9  47.5  56.0  16.8 
100  65.1  19.1  21.2  6.4 
200  32.2  9.4  18.8  5.7 
" Mouse splenic T  cells were stimulated  for 48 h  with ionomycin (250 ng/ml) plus  PMA (10 ng/ml). 
* Cell proliferation  was  measured  by pulsing the cultures  with 2/xCi[3H]TdR for 4 h. 
S Each value is the mean of triplicate  wells. 
U  Control proliferative  response of cells stimulated  wth ionomycin plus  PMA in the absence of drug. 
whether I.,685,818 would exert any of the side effects previ- 
ously noted with FK-506 in animal models (10). Although 
highly sensitive to the toxic effects of FK-506 (34) or RAP 
(12), dogs were unaffected by a 2-wk oral treatment with 
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Figure  5.  L-685,818 reverses the suppression of T cell proliferative re- 
sponses by FK-506 (a) or RAP (b) even when added after either immunosul> 
pressant  to the cultures.  (a) Mouse splenic T  cells were activated with 
ionomycin plus PMA, and FK-506 (1.2 riM) was added at the initiation 
of the cultures.  Replicate wells received L-685,818 (125 nM) either at the 
same time as FK-506  (t  =  0) or at various  times thereafter.  (b) Mouse 
splenic T cells were activated with IL-2 plus PMA and RAP (1.1 riM) was 
added at the initiation of the cultures.  Replicate wells received L-685,818 
(125 riM) either at the same time as RAP (t  =  0) or at various  times 
thereafter.  In both (a) and (b), the cultures were harvested after 48 h of 
incubation after a 6-h pulse with [3H]TdR.. The results were expressed 
as percent  of the control response obtained  with ceils stimulated  in the 
absence of compound (ionomycin  +  PMA  =  425  x  103 clan, IL-2 + 
PMA  =  623  x  103cpm). 
L-685,818 at doses as high as 25 mg/kg/d, which gave plasma 
drug levels >2  /xg/ml.  Similarly,  oral  administration  of 
D685,818 in rats for 2 wk at 25 mg/kg/d, failed to cause 
the nephrotoxicity or behavioral changes that have been ob- 
served with FK-506 (10, 11). Therefore, b685,818  is devoid 
of the toxicity known to be associated with FK-506. 
L685,818 Blocks the Nephrotoxic Action of  FK-506.  To ex- 
amine the possibility that L-685,818 could antagonize  FK- 
506-induced toxicity, we used an acute model in BALB/c mice, 
where the nephrotoxic potential of FK-506 was enhanced by 
cotreatment of the animals with the inhibitor of cytochrome 
P450, SKF-525A (31). Consistent with the recently demon- 
strated role of P450 enzymes in the metabolism of FK-506 
(35), we found that SKF-525A augmented the serum level 
of FK-506 (not shown). Under these conditions,  two daily 
intravenous injections of FK-506 in doses ranging from 3.1 
to 12.5 mg/kg were sufficient to induce a significant eleva- 
tion of BUN levels. I.-683,590 (50 mg/kg) was also found 
to raise BUN concentration, whereas RAP (100 mg/kg) had 
no effect on this parameter, although it caused mortality (Table 
2).  In contrast,  the same protocol of treatment with 100 
mg/kg of b685,818  did not produce any increase of BUN 
or mortality (Table 2 and Fig. 7). It is most interesting that 
administration of this high dose of b685,818,  together with 
toxic doses of FK-506, prevented almost completely the rise 
in BUN observed with FK-506 alone (Fig. 7 a). The dose- 
dependent nature of the antagonism is demonstrated in Fig. 
7 b, where the animals were given a constant dose of FK-506 
and varying doses of I~685,818. Therefore, L-685,818 is a po- 
tent antagonist of the acute nephrotoxic effect of FK-506 in 
this  murine model  Additional  experiments  (not  shown) 
demonstrated that b685,818  does not block CsA-mediated 
nephrotoxicity. 
756  Immunosuppression  and Toxicity by FK-506 are Mechanistically  Related Table  2.  Effects  of Two Daily Intravenous Injections of FK-506, 
L-683,590,  RAP,  or L-685,818  on BUN Levels in BALB/c 
Mice Cotreated with SKF-525A * 
Treatment  BUN  (mg/dl) 
Expt.  no.  (Dose,  mg/kg)  Mean (SEM)  p*  Mortality 
1  Vehicle  14.4  (0.5)  0/6 
FK-506 (12.5)  61.0  (16.2)  0.007  2/6 
L-683,590 (50)  50.2  (11.4)  0.007  1/6 
2  Vehicle  20.7  (1.3)  0/6 
FK-506 (12.5)  34.8  (1.7)  0.0001  0/6 
RAP (100)  22.2  (1.7)  0.5  3/8 
3  Vehicle  14.7  (0.9)  0/6 
FK-506 (12.5)  85.8  (15.6)  0.0007  1/6 
L-685,818  (100)  16.2 (0.7)  0.2  0/6 
Figure 6.  L-685,818  blocks the inhibitory  effects ofFK-506 (a) and RAP 
(b) on lymphokine mRNA induction. (a) DO-11.10 cells were activated 
with ionomycin plus PMA in presence or absence of various concentra- 
tions of FK-506, without or with L-685,818  (12 #M). The cells were har- 
vested after 3 h of culture, and total RNA was extracted and blotted onto 
a nitrocellulose filter. The blot was hybridized'with  the Ib2 cDNA probe, 
stripped, and rehybridized with the actin cDNA probe.  (b) YAC-1 cells 
were activated with IL-1 plus PMA in presence or absence of various con- 
centrations of RAP, without or with b685,818 (12 ~tM). The cells were 
harvested after 20 h of culture and total RNA was extracted and blotted 
onto a nitrocellulose filter. The blot was hybridized with the IFN-T  cDNA 
probe,  stripped,  and rehybridized with the actin cDNA probe. 
Discussion 
The present  study exploits  the unique pharmacological 
properties of b685,818  to investigate the mechanism of ac- 
tion of FK-506 with respect to its biochemical target for im- 
munosuppression,  and the relationship between this target 
and toxicity, b685,818 differs from FK-506 at two positions. 
Although the aUyl to ethyl substitution at the C21 position 
results in a two to threefold loss in immunosuppressive potency, 
it is the addition of a hydroxyl group at the C18 position 
of the macrolide ring that converts the molecule to an an- 
tagonist. Recent x-ray crystallographic and nuclear magnetic 
resonance  studies  indicate  that  I.-685,818  associates  with 
FKBP-12 through its pipecolic acid portion, in a manner iden- 
tical to FK-506 (Becker, J., manuscript in preparation). Hence, 
it is not surprising that FK-506 and L-685,818 have equiva- 
lent activities in binding to FKBP-12  and in inhibiting its 
PPlase activity, since it is their common "face" that is respon- 
sible for these activities. Such observations are consistent with 
earlier studies using 506BD  and RAP  (22). 
The observation that the physical interaction with FKBP-12 
and the inhibition of  PPIase may be necessary but not sufficient 
for immunosuppression has led to the hypothesis that the 
drugs must interact with other cellular components to dis- 
rupt the signaling processes of T cell activation (1, 2). This 
hypothesis is supported by the recent finding that the corn- 
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*  Mice received an intraperitoneal  injection of SKF-525A (75 mg/kg) 
2 h before intravenous administration of the compounds.  The animals 
were treated  for 2 consecutive d  and killed the next day. 
t Statistical significance determined  by Student's t test. 
plex formed between FKo506 and FKBP-12  interacts with 
the  CaZ+-calmodulin-dependent phosphatase,  calcineurin, 
and inhibits its phosphatase activity in vitro (26).  We found 
here that I.-685,818 is unable to alter the activity of  calcineurin 
in such a system, even when tested at concentrations up to 
40-fold greater than FK-506, whereas b683,590  did inhibit 
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Figure 7.  L-685,818 does  not increase BUN but blocks  the BUN 
elevating effect of FK-506 in BALB/c mice cotreated with SKF-525A. The 
mice received SKF-525A (75 mg/kg) intraperitoneaUy 2 h before intrave- 
nous injection of FK-506 or 1--685,818 either alone or in combination. 
Control (Ct) mice received  SKF-525A and the vehicle  alone. All mice were 
treated on 2 consecutive d and were bled and killed the following day. 
(a) I.-685,818 was administered at 100 mg/kg/d ([]). FK-506 was given 
at 1.6, 3.1, or 6.2 mg/kg/d either alone (g3) or together with I--685,818 
(100 mg/kg/d,  m). The results are the pooled data from three experi- 
ments, with each group including a total of 15-18 mice. (b) FK-506 was 
given at 6.2 mg/kg/d either alone ([]) or together with various doses 
of I.,685,818 (I). The results are the pooled data from two experiments, 
with each group including  a total of  9-12 mice. The statistical significances 
(Student's t test) of the differences in BUN'between the groups treated 
with FK-506 alone and the control group, and between the groups treated 
with FK-506 alone or with 1.,685,818 are indicated ( *  ) p <0.1, ( * * ) p <0.01. this activity with a potency approximatdy twofold lower than 
FK-506. This demonstrates  a clear-cut corrdation between 
the ability of the drugs complexed to FKBP-12 to interfere 
with the phosphatase activity of calcineurin and their ability 
to suppress T cell activation induced in a Ca2+-dependent 
manner. Such a correlation  suggests that the inhibition of 
caldneurin enzymatic function by the FKBP-drug complex 
may be involved in the mechanism of immunosuppressive ac- 
tion of the drugs.  Although a similar conclusion had been 
made based on studies with RAP (26), the strict concordance 
between the biochemical and cellular observations produced 
by a subtle structural change, such as the 18-hydroxy substi- 
tution, further solidifies this model. 
Are the molecular entities defined in the current in vitro 
caldneurin assay system the relevant members of the com- 
plex that mediate immunosuppressive activity in vivo? There 
are several  reasons to consider this question. First, the in vitro 
system used in both the present  and previous (26) studies 
is based on the interaction of heterologous proteins (bovine 
calcineurin and calmodulin with human FKBP-12). Second, 
the existence of several  isoenzymes of calcineurin (25) should 
be noted. Third, a number of minor forms of FKBPs have 
now been identified in mammalian cells (36-38). 
Recent genetic experiments strongly implicate calcineurin 
as a component of a drug-sensitive  signal transduction pathway 
in T cells. O'Keefe, et al. (38a) have  demonstrated that trans- 
fection of a mutant, constitutively active, catalytic subunit 
of calcineurin into Jurkat cells synergizes with PMA alone 
to activate the II~2 promoter in an FK-506- and CsA-sensitive 
manner. Although similar experiments have not been per- 
formed with FKBP-12, several results have called into ques- 
tion the assumption  that the most abundant immunosup- 
pressant receptors must mediate all the biological effects of 
FK-605 and CsA.  In yeast, deletion of FKBP-12 does not 
confer resistance to the growth inhibitory effects of FK-506 
(39), suggesting the existence  of other FKBP family members. 
Pharmacological  experiments with CsA analogs also suggested 
that Cyp A may not be the member of this family to mediate 
the immunosuppressive activity of CsA (21). Thus, whereas 
genetic studies dearly put calcineurin in the drug-sensitive 
signal transduction pathway, experiments performed to date 
do not permit us to identify which FKBP family member 
is the most relevant effector of calcineurin complex forma- 
tion in vivo. 
The identification  ofb685,818 as the most potent antagonist 
of  both FK-506 and RAP-mediated immunosuppression syn- 
thesized to date has allowed us to explore the nature of the 
functional receptor of these compounds from a different per- 
spective. Sehild ~n~lysis  was used to demonstrate that b685,818 
interacted with a single receptor species when either FK-506 
or RAP was used as the agonist. Furthermore, since b685,818 
could be added to the cultures  several hours after FK-506, 
and since FK-506 is known to penetrate and reach equilib- 
rium within the cells in <20 rain (14), we concluded that 
the antagonism of b685,818  does not reflect inhibition of 
a transport mechanism. The most straightforward conclu- 
sion from these data is that b685,818  antagonizes FK-506 
and RAP through their interaction with a common cellular 
receptor, a notion already suggested by the fact that the two 
drugs antagonize each other's action with similar potencies 
(9). More through analysis suggests alternative possibilities, 
however. The affinities derived by Schild analysis (4-8 riM) 
differ significantly from those estimated from FKBP-12 com- 
petitive binding measurements (0.7 riM). This diffgrence  may 
be due to relative abundance of the relevant drug receptor 
within the cell. However, given the fact that the intracellular 
concentration of FKBP-12 is '~5-10/~M (Dumont, F. et al., 
manuscript in preparation), one might expect that even larger 
concentrations of I.-685,818 would be required to observe an- 
tagonism and that the antagonism  might be noncompeti- 
tive. Taken together, Ka estimates derived from the Sehild 
analysis are not entirely consistent with the assumption that 
the antagonist and agonists are distributed uniformly within 
the FKBP-12 cytosolic  receptor pool. Indeed, FK-506 and RAP 
may interact with receptors that are in lower abundance than 
FKBP-12, or may bind preferentially  to  a distinct  subset 
of FKBP-12 molecules within the cell. Therefore, although 
FKBP-12 appears as the most plausible intracellular  target 
for these compounds, we cannot exclude the possibility that 
another known, or as yet undiscovered  FKBP may  be involved. 
The present study provides important insights into the rela- 
tionship between the immunosuppressive  and toxic effects 
of FK-506. Along with its lack of immunosuppressive  ac- 
tivity, I.-685,818 did not elicit any of the side effects known 
to occur after FK-506 treatment in several animal species, in- 
cluding the gastrointestinal pathology seen in dogs (34) and 
the nephrotoxicity observed in rats (11). Using a mouse model 
where the nephrotoxic effect  of FK-506 was enhanced by coad- 
ministration of the I}450 inhibitor SKF-525A (31), we found 
that L-685,818 produced little or no elevation of BUN, even 
when given at doses 5-10-fold greater than nephrotoxic doses 
of FK-506. Since interfering with FK-506 metabolism poten- 
tiates the toxicity of the drug, it is likely that the parent com- 
pound, rather than metabolites, may be primarily responsible 
for the induction of nephrotoxicity. Furthermore, the use of 
an inhibitor of macrolide metabolism also minimizes the pos- 
sibility that b685,818  could be modified in vivo. The most 
striking observation made with this modal, however, is that 
b685,818 reversed  the nephrotoxic action of FK-506 in a dose- 
dependent manner. 
The finding that the toxic effects of  FK-506 can be reversed 
by the same antagonist that blocks FK-506 immunosuppres- 
sion strongly suggests that the mechanisms of immunosup- 
pression and toxicity are related. FK-506 may therefore affect 
biochemical processes that are part of signal transduction 
pathways shared in common by lymphoid calls and by non- 
lymphoid calls in  the target toxicity organs.  As  for im- 
munosuppression,  it is unlikely that these processes involve 
inhibition of PPlase activity, which is similar to the conclu- 
sion reached in an analysis of CsA analogs (21). Instead, the 
toxicity of FK-506 may be linked to the ability of the drug- 
FKBP-12 complex to inhibit the phosphatase activity of cal- 
cineurin. This conclusion may also explain why FK-506 and 
CsA share such similar patterns of toxicity (11). 
Since FKBPs, Cyps, and calcineurins are widely distributed, 
it may be surprising  that FK-506 and CsA do not produce 
758  lmmunosuppression and Toxicity by FK-506 are Mechanistically Related even more toxicity. There may be several reasons for the ap- 
parent sdectivity of the drugs. Although calcineurin is present 
in a variety of tissues, it differs in abundance and isoenzyme 
distribution pattern (25),  and may have diverse roles in the 
physiology of the cells. The substrates for calcineurin may 
also differ among cells. In addition, selectivity could be related 
to the tissue distribution of related FKBPs that would confer 
the appropriate aff~ty and fimctional ability of the drug com- 
plex to interfere with calcineurin. Nevertheless,  the finding 
that immunosuppression and toxicity of FK-506 are mech- 
anistically related will make it difficult to dissociate  the im- 
munosuppressive activity and toxic effects of molecules that 
use such common biochemical pathways. 
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